"The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemi"...
- Patient Information:
Details with Side Effects
NIASPAN is contraindicated in the following conditions:
- Active liver disease or unexplained persistent elevations in hepatic transaminases [see WARNINGS AND PRECAUTIONS]
- Patients with active peptic ulcer disease
- Patients with arterial bleeding
- Hypersensitivity to niacin or any component of this medication [see ADVERSE REACTIONS]
Last reviewed on RxList: 3/12/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Niaspan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Tips to keep it under control.